Metagenomi advances MGX-001 toward IND filing
Metagenomi said MGX-001 has preclinical durability and safety data and plans to file an IND in Q4 2026. The company said it had $120.7 million of cash runway through Q4 2027.
Metagenomi Therapeutics said a September 2026 corporate presentation highlighted MGX-001 preclinical durability and safety data, along with a plan to file an IND in Q4 2026. Original SEC Filing: Metagenomi Therapeutics, Inc. [ MGX ] - 8-K - Sep. 21, 2026